{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T20:04:18Z","timestamp":1789502658379,"version":"build-2803163510"},"reference-count":94,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Clinics of North America"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.mcna.2021.11.006","type":"journal-article","created":{"date-parts":[[2022,2,25]],"date-time":"2022-02-25T16:32:39Z","timestamp":1645806759000},"page":"299-312","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Triglycerides"],"prefix":"10.1016","volume":"106","author":[{"given":"Najdat","family":"Bazarbashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.mcna.2021.11.006_bib1","doi-asserted-by":"crossref","first-page":"67","DOI":"10.2174\/1573403X14666180123165542","article-title":"Hypertriglyceridemia - common causes, prevention and treatment strategies","volume":"14","author":"Rygiel","year":"2018","journal-title":"Curr Cardiol Rev"},{"key":"10.1016\/j.mcna.2021.11.006_bib2","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S0140-6736(14)61177-6","article-title":"Triglycerides and cardiovascular disease","volume":"384","author":"Nordestgaard","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.mcna.2021.11.006_bib3","doi-asserted-by":"crossref","first-page":"e015801","DOI":"10.1161\/JAHA.119.015801","article-title":"Association of hypertriglyceridemia with all-cause mortality and atherosclerotic cardiovascular events in a low-risk italian population: The TG-REAL retrospective cohort analysis","volume":"9","author":"Arca","year":"2020","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.mcna.2021.11.006_bib4","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1161\/CIRCULATIONAHA.113.003008","article-title":"Elevated remnant cholesterol causes both low-grade inflammation and ischemic heart disease, whereas elevated low-density lipoprotein cholesterol causes ischemic heart disease without inflammation","volume":"128","author":"Varbo","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.mcna.2021.11.006_bib5","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.atherosclerosis.2006.12.018","article-title":"Ethnic differences in the ability of triglyceride levels to identify insulin resistance","volume":"196","author":"Sumner","year":"2008","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.mcna.2021.11.006_bib6","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ijcard.2017.12.069","article-title":"Prevalence of dyslipidemia and achievement of low-density lipoprotein cholesterol targets in Chinese adults: A nationally representative survey of 163,641 adults","volume":"260","author":"Zhang","year":"2018","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.mcna.2021.11.006_bib7","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1093\/eurheartj\/ehz785","article-title":"Clinical review on triglycerides","volume":"41","author":"Laufs","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.mcna.2021.11.006_bib8","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s12944-017-0511-9","article-title":"Severe hypertriglyceridemia in Norway: prevalence, clinical and genetic characteristics","volume":"16","author":"Retterstol","year":"2017","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.mcna.2021.11.006_bib9","doi-asserted-by":"crossref","first-page":"213","DOI":"10.5603\/KP.2016.0029","article-title":"Prevalence of lipid abnormalities in Poland. The NATPOL 2011 survey","volume":"74","author":"Zdrojewski","year":"2016","journal-title":"Kardiol Pol"},{"key":"10.1016\/j.mcna.2021.11.006_bib10","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s12933-015-0268-2","article-title":"PROMETHEUS: an observational, cross-sectional, retrospective study of hypertriglyceridemia in Russia","volume":"14","author":"Karpov","year":"2015","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.mcna.2021.11.006_bib11","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1177\/2047487315589011","article-title":"Cardiovascular health in Italy. Ten-year surveillance of cardiovascular diseases and risk factors: Osservatorio Epidemiologico Cardiovascolare\/Health Examination Survey 1998-2012","volume":"22","author":"Giampaoli","year":"2015","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.mcna.2021.11.006_bib12","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s40119-020-00170-x","article-title":"Prevalence of US Adults with Triglycerides\u00a0>\/= 150\u00a0mg\/dl: NHANES 2007-2014","volume":"9","author":"Fan","year":"2020","journal-title":"Cardiol Ther"},{"key":"10.1016\/j.mcna.2021.11.006_bib13","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/dom.13921","article-title":"Risk of cardiovascular events in patients with hypertriglyceridaemia: A review of real-world evidence","volume":"22","author":"Toth","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.mcna.2021.11.006_bib14","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1161\/CIRCULATIONAHA.106.637793","article-title":"Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies","volume":"115","author":"Sarwar","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.mcna.2021.11.006_bib15","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/0002-9149(92)90550-I","article-title":"Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective Cardiovascular Munster study","volume":"70","author":"Assmann","year":"1992","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.mcna.2021.11.006_bib16","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1001\/jama.1993.03500230097036","article-title":"Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)","volume":"269","year":"1993","journal-title":"JAMA"},{"key":"10.1016\/j.mcna.2021.11.006_bib17","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1161\/CIR.0b013e3182160726","article-title":"Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association","volume":"123","author":"Miller","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.mcna.2021.11.006_bib18","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.amjcard.2010.11.008","article-title":"Prevalence of severe (500 to 2,000\u00a0mg\/dl) hypertriglyceridemia in United States adults","volume":"107","author":"Christian","year":"2011","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.mcna.2021.11.006_bib19","first-page":"e1082","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.mcna.2021.11.006_bib20","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1016\/S0735-1097(98)00083-7","article-title":"Normal triglyceride levels and coronary artery disease events: the Baltimore Coronary Observational Long-Term Study","volume":"31","author":"Miller","year":"1998","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.mcna.2021.11.006_bib21","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1161\/CIRCOUTCOMES.115.002104","article-title":"Elevated Triglyceride Level Is Independently Associated With Increased All-Cause Mortality in Patients With Established Coronary Heart Disease: Twenty-Two-Year Follow-Up of the Bezafibrate Infarction Prevention Study and Registry","volume":"9","author":"Klempfner","year":"2016","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.mcna.2021.11.006_bib22","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.jacl.2020.04.009","article-title":"The association between triglycerides and incident cardiovascular disease: What is \"optimal","volume":"14","author":"Aberra","year":"2020","journal-title":"J\u00a0Clin Lipidol"},{"key":"10.1016\/j.mcna.2021.11.006_bib23","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1161\/01.CIR.0000035280.64322.31","article-title":"New perspectives on atherogenesis: role of abnormal triglyceride-rich lipoprotein metabolism","volume":"106","author":"Ginsberg","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.mcna.2021.11.006_bib24","unstructured":"Feingold KR, Grunfeld C. Introduction to Lipids and Lipoproteins. In: Feingold KR, Anawalt B, Boyce A, et\u00a0al., editors. Endotext. South Dartmouth (MA); MDText.com, Inc: 2000."},{"key":"10.1016\/j.mcna.2021.11.006_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2009.12.027","article-title":"The metabolism of triglyceride-rich lipoproteins revisited: new players, new insight","volume":"211","author":"Dallinga-Thie","year":"2010","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.mcna.2021.11.006_bib26","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.jacc.2012.08.1026","article-title":"Remnant cholesterol as a causal risk factor for ischemic heart disease","volume":"61","author":"Varbo","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.mcna.2021.11.006_bib27","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1161\/CIRCRESAHA.115.306249","article-title":"Triglyceride-Rich Lipoproteins and Atherosclerotic Cardiovascular Disease: New Insights From Epidemiology, Genetics, and Biology","volume":"118","author":"Nordestgaard","year":"2016","journal-title":"Circ Res"},{"key":"10.1016\/j.mcna.2021.11.006_bib28","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.cca.2005.12.013","article-title":"The oxidative modification hypothesis of atherosclerosis: the comparison of atherogenic effects on oxidized LDL and remnant lipoproteins in plasma","volume":"367","author":"Nakajima","year":"2006","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.mcna.2021.11.006_bib29","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1042\/CS20070308","article-title":"understanding an emerging cardiovascular risk factor","volume":"114","author":"Ooi","year":"2008","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.mcna.2021.11.006_bib30","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s11883-019-0791-9","article-title":"Emerging Evidence that ApoC-III Inhibitors Provide Novel Options to Reduce the Residual CVD","volume":"21","author":"Taskinen","year":"2019","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.mcna.2021.11.006_bib31","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1172\/JCI111711","article-title":"Modulation of lipoprotein lipase activity by apolipoproteins. Effect of apolipoprotein C-III","volume":"75","author":"Wang","year":"1985","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.mcna.2021.11.006_bib32","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1093\/eurheartj\/ehu500","article-title":"Triglycerides on the rise: should we swap seats on the seesaw?","volume":"36","author":"Libby","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.mcna.2021.11.006_bib33","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1161\/ATVBAHA.120.314368","article-title":"Apolipoprotein CIII Deficiency Protects Against Atherosclerosis in Knockout Rabbits","volume":"40","author":"Yan","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.mcna.2021.11.006_bib34","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1307095","article-title":"Loss-of-function mutations in APOC3, triglycerides, and coronary disease","volume":"371","author":"Crosby","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.mcna.2021.11.006_bib35","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1126\/science.1161524","article-title":"A\u00a0null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection","volume":"322","author":"Pollin","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.mcna.2021.11.006_bib36","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1016\/j.jacc.2015.08.866","article-title":"Association of APOC3 Loss-of-Function Mutations With Plasma Lipids and Subclinical Atherosclerosis: The Multi-Ethnic BioImage Study","volume":"66","author":"Natarajan","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.mcna.2021.11.006_bib37","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1161\/01.CIR.82.2.495","article-title":"Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk","volume":"82","author":"Austin","year":"1990","journal-title":"Circulation"},{"key":"10.1016\/j.mcna.2021.11.006_bib38","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/0002-9343(93)90144-E","article-title":"Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B","volume":"94","author":"Chait","year":"1993","journal-title":"Am J Med"},{"key":"10.1016\/j.mcna.2021.11.006_bib39","doi-asserted-by":"crossref","first-page":"22i","DOI":"10.1016\/S0002-9149(02)02632-2","article-title":"Measurement issues related to lipoprotein heterogeneity","volume":"90","author":"Otvos","year":"2002","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.mcna.2021.11.006_bib40","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.jacc.2018.03.541","article-title":"Low-Density Lipoprotein Triglycerides: Widening the Atherogenic Landscape in CVD Risk Assessment","volume":"72","author":"Miller","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.mcna.2021.11.006_bib41","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1161\/01.CIR.0000146898.06923.80","article-title":"Low-density lipoprotein triglycerides associated with low-grade systemic inflammation, adhesion molecules, and angiographic coronary artery disease: the Ludwigshafen Risk and Cardiovascular Health study","volume":"110","author":"Marz","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.mcna.2021.11.006_bib42","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0022-2275(20)41520-2","article-title":"Lipid and protein structures in the permeability barrier of mammalian epidermis","volume":"33","author":"Downing","year":"1992","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.mcna.2021.11.006_bib43","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0022-2275(20)41523-8","article-title":"Abnormalities of low density lipoproteins in normolipidemic type II diabetic and nondiabetic patients with coronary artery disease","volume":"33","author":"Tilly-Kiesi","year":"1992","journal-title":"J\u00a0Lipid Res"},{"issue":"Suppl 2","key":"10.1016\/j.mcna.2021.11.006_bib44","first-page":"28","article-title":"Effect of gemfibrozil on lipoprotein concentrations in different types of hyperlipoproteinaemia","volume":"69","author":"Olsson","year":"1976","journal-title":"Proc R Soc Med"},{"key":"10.1016\/j.mcna.2021.11.006_bib45","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jacc.2018.04.050","article-title":"Remnant-Like Particle Cholesterol, Low-Density Lipoprotein Triglycerides, and Incident Cardiovascular Disease","volume":"72","author":"Saeed","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.mcna.2021.11.006_bib46","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.atherosclerosis.2016.06.019","article-title":"Relationship of baseline HDL subclasses, small dense LDL and LDL triglyceride to cardiovascular events in the AIM-HIGH clinical trial","volume":"251","author":"Albers","year":"2016","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.mcna.2021.11.006_bib47","first-page":"1211","article-title":"Novel genetic loci associated with long-term deterioration in blood lipid concentrations and coronary artery disease in European adults","volume":"46","author":"Varga","year":"2017","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.mcna.2021.11.006_bib48","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/ejhg.2008.222","article-title":"Unraveling hyperlipidemia type III (dysbetalipoproteinemia), slowly","volume":"17","author":"Schaefer","year":"2009","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.mcna.2021.11.006_bib49","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jacl.2018.10.006","article-title":"Severe hypertriglyceridemia is primarily polygenic","volume":"13","author":"Dron","year":"2019","journal-title":"J\u00a0Clin Lipidol"},{"key":"10.1016\/j.mcna.2021.11.006_bib50","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/0026-0495(76)90089-5","article-title":"Myocardial infarction in the familial forms of hypertriglyceridemia","volume":"25","author":"Brunzell","year":"1976","journal-title":"Metabolism"},{"key":"10.1016\/j.mcna.2021.11.006_bib51","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1161\/01.CIR.85.6.2025","article-title":"Familial lipoprotein disorders in patients with premature coronary artery disease","volume":"85","author":"Genest","year":"1992","journal-title":"Circulation"},{"key":"10.1016\/j.mcna.2021.11.006_bib52","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1161\/CIRCULATIONAHA.106.675355","article-title":"Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study","volume":"116","author":"Fox","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.mcna.2021.11.006_bib53","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.jacl.2014.07.007","article-title":"National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1 - executive summary","volume":"8","author":"Jacobson","year":"2014","journal-title":"J\u00a0Clin Lipidol"},{"key":"10.1016\/j.mcna.2021.11.006_bib54","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S2213-8587(13)70191-8","article-title":"The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management","volume":"2","author":"Hegele","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.mcna.2021.11.006_bib55","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1373\/clinchem.2010.157164","article-title":"Nonfasting lipids, lipoproteins, and apolipoproteins in individuals with and without diabetes: 58 434 individuals from the Copenhagen General Population Study","volume":"57","author":"Langsted","year":"2011","journal-title":"Clin Chem"},{"key":"10.1016\/j.mcna.2021.11.006_bib56","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1093\/eurheartj\/ehw152","volume":"37","author":"Nordestgaard","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.mcna.2021.11.006_bib57","doi-asserted-by":"crossref","first-page":"S516","DOI":"10.1055\/s-2001-15114","article-title":"Triglycerides, fatty acids and insulin resistance--hyperinsulinemia","volume":"109","author":"Kraegen","year":"2001","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"10.1016\/j.mcna.2021.11.006_bib58","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1249\/00003677-199600240-00009","article-title":"Effects of acute and chronic exercise on fat metabolism","volume":"24","author":"Martin","year":"1996","journal-title":"Exerc Sport Sci Rev"},{"key":"10.1016\/j.mcna.2021.11.006_bib59","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s40279-013-0110-5","article-title":"Differential effects of aerobic exercise, resistance training and combined exercise modalities on cholesterol and the lipid profile: review, synthesis and recommendations","volume":"44","author":"Mann","year":"2014","journal-title":"Sports Med"},{"key":"10.1016\/j.mcna.2021.11.006_bib60","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/clc.23104","article-title":"Aerobic exercise reduces triglycerides by targeting apolipoprotein C3 in patients with coronary heart disease","volume":"42","author":"Wang","year":"2019","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.mcna.2021.11.006_bib61","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s12944-015-0085-3","article-title":"Physical activity, sedentary behavior time and lipid levels in the Observation of Cardiovascular Risk Factors in Luxembourg study","volume":"14","author":"Crichton","year":"2015","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.mcna.2021.11.006_bib62","doi-asserted-by":"crossref","first-page":"e177","DOI":"10.1016\/j.jacc.2019.03.010","article-title":"2019 ACC\/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"74","author":"Arnett","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.mcna.2021.11.006_bib63","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/j.jacc.2010.09.073","article-title":"The effect of Mediterranean diet on metabolic syndrome and its components: a meta-analysis of 50 studies and 534,906 individuals","volume":"57","author":"Kastorini","year":"2011","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.mcna.2021.11.006_bib64","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jacl.2015.12.003","article-title":"Lipids and bariatric procedures part 1 of 2: Scientific statement from the National Lipid Association, American Society for Metabolic and Bariatric Surgery, and Obesity Medicine Association: EXECUTIVE SUMMARY","volume":"10","author":"Bays","year":"2016","journal-title":"J\u00a0Clin Lipidol"},{"key":"10.1016\/j.mcna.2021.11.006_bib65","doi-asserted-by":"crossref","first-page":"66B","DOI":"10.1016\/S0002-9149(98)00041-1","article-title":"Comparison of statins in hypertriglyceridemia","volume":"81","author":"Stein","year":"1998","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.mcna.2021.11.006_bib66","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/MOL.0b013e3283613a68","article-title":"Recent advances in niacin and lipid metabolism","volume":"24","author":"Kamanna","year":"2013","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.mcna.2021.11.006_bib67","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.jacc.2004.10.031","article-title":"Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials","volume":"45","author":"Birjmohun","year":"2005","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.mcna.2021.11.006_bib68","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","article-title":"Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy","volume":"365","author":"Investigators","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.mcna.2021.11.006_bib69","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/eurheartj\/eht055","article-title":"HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin\/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment","volume":"34","author":"Group","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.mcna.2021.11.006_bib70","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1056\/NEJMc1006407","article-title":"Combination lipid therapy in type 2 diabetes","volume":"363","author":"Sacks","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.mcna.2021.11.006_bib71","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/CRD.0b013e31816b43d3","article-title":"Fibrate therapy: an update","volume":"16","author":"Remick","year":"2008","journal-title":"Cardiol Rev"},{"key":"10.1016\/j.mcna.2021.11.006_bib72","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus","volume":"362","author":"Group","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.mcna.2021.11.006_bib73","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/MOL.0b013e328341a5a8","article-title":"Role of fibrates in cardiovascular disease prevention, the ACCORD-Lipid perspective","volume":"22","author":"Elam","year":"2011","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.mcna.2021.11.006_bib74","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ahj.2018.09.011","article-title":"Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study","volume":"206","author":"Pradhan","year":"2018","journal-title":"Am Heart J"},{"key":"10.1016\/j.mcna.2021.11.006_bib75","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.mcna.2021.11.006_bib76","doi-asserted-by":"crossref","first-page":"391","DOI":"10.2217\/fca-2019-0054","article-title":"Icosapent ethyl for hypertriglyceridemia: insights from the REDUCE-IT Trial","volume":"15","author":"Miller","year":"2019","journal-title":"Future Cardiol"},{"key":"10.1016\/j.mcna.2021.11.006_bib77","series-title":"FDA approves use of drug to reduce risk of cardiovascular events in certain adult patient groups","year":"2019"},{"key":"10.1016\/j.mcna.2021.11.006_bib78","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.jacl.2019.10.014","article-title":"National Lipid Association Scientific Statement on the use of icosapent ethyl in statin-treated patients with elevated triglycerides and high or very-high ASCVD risk","volume":"13","author":"Orringer","year":"2019","journal-title":"J\u00a0Clin Lipidol"},{"key":"10.1016\/j.mcna.2021.11.006_bib79","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1080\/14779072.2020.1749596","article-title":"Icosapent ethyl: drug profile and evidence of reduced residual cardiovascular risk in patients with statin-managed LDL-C cholesterol","volume":"18","author":"Bazarbashi","year":"2020","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"10.1016\/j.mcna.2021.11.006_bib80","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1093\/eurheartj\/ehaa652","article-title":"Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial","volume":"41","author":"Budoff","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.mcna.2021.11.006_bib81","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1001\/jama.2020.22258","article-title":"Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical Trial","volume":"324","author":"Nicholls","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.mcna.2021.11.006_bib82","doi-asserted-by":"crossref","unstructured":"Khan S, Lone AN, Khan MS, et\u00a0al. Effect of omega-3 fatty acids on cardiovascular outcomes: A systematic review and meta-analysis. 2021;838.","DOI":"10.1016\/j.eclinm.2021.100997"},{"key":"10.1016\/j.mcna.2021.11.006_bib83","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1161\/ATVBAHA.119.313286","article-title":"Emerging Mechanisms of Cardiovascular Protection for the Omega-3 Fatty Acid Eicosapentaenoic Acid","volume":"40","author":"Mason","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.mcna.2021.11.006_bib84","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/s11886-020-01356-4","article-title":"Icosapent Ethyl: Niche Drug or for the Masses?","volume":"22","author":"Bazarbashi","year":"2020","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.mcna.2021.11.006_bib85","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1056\/NEJMoa1715944","article-title":"Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome","volume":"381","author":"Witztum","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.mcna.2021.11.006_bib86","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.bbalip.2011.10.010","article-title":"Regulation of triglyceride metabolism by Angiopoietin-like proteins","volume":"1821","author":"Mattijssen","year":"2012","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.mcna.2021.11.006_bib87","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1612790","article-title":"Genetic and pharmacologic inactivation of ANGPTL3 and cardiovascular disease","volume":"377","author":"Dewey","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.mcna.2021.11.006_bib88","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1056\/NEJMoa1701329","article-title":"Cardiovascular and metabolic effects of ANGPTL3 antisense oligonucleotides","volume":"377","author":"Graham","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.mcna.2021.11.006_bib89","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/j.jacl.2016.08.002","article-title":"Efficacy and safety of gemcabene as add-on to stable statin therapy in hypercholesterolemic patients","volume":"10","author":"Stein","year":"2016","journal-title":"J\u00a0Clin Lipidol"},{"key":"10.1016\/j.mcna.2021.11.006_bib90","series-title":"Gemcabene meets primary endpoint in INDIGO-1 study of severe hypertriglyceridemia (SHTG) Patients","author":"Newswire","year":"2018"},{"key":"10.1016\/j.mcna.2021.11.006_bib91","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/s41574-020-0386-0","article-title":"The therapeutic potential of FGF21 in metabolic diseases: from bench to clinic","volume":"16","author":"Geng","year":"2020","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.mcna.2021.11.006_bib92","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.mcna.2021.11.006_bib93","doi-asserted-by":"crossref","first-page":"e673","DOI":"10.1161\/CIR.0000000000000709","article-title":"Omega-3 fatty acids for the management of hypertriglyceridemia: a science advisory from the american heart association","volume":"140","author":"Skulas-Ray","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.mcna.2021.11.006_bib94","doi-asserted-by":"crossref","first-page":"S111","DOI":"10.2337\/dc20-S010","article-title":"10. Cardiovascular disease and risk management: standards of medical care in diabetes-2020","volume":"43","author":"American Diabetes","year":"2020","journal-title":"Diabetes Care"}],"container-title":["Medical Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025712521001656?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025712521001656?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T01:46:57Z","timestamp":1758419217000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025712521001656"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":94,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["S0025712521001656"],"URL":"https:\/\/doi.org\/10.1016\/j.mcna.2021.11.006","relation":{},"ISSN":["0025-7125"],"issn-type":[{"value":"0025-7125","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Triglycerides","name":"articletitle","label":"Article Title"},{"value":"Medical Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mcna.2021.11.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}